Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

EADV 2020 | References: General Sessions

Other 2020

  1. Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (Fdg-pet/ct): a pilot study. Arch Dermatol. 2011;147(9):1031-1039.
  2. Naik HB, Natarajan B, Stansky E, et al. Severity of psoriasis associates with aortic vascular inflammation detected by fdg pet/ct and neutrophil activation in a prospective observational study. Arterioscler Thromb Vasc Biol. 2015;35(12):2667-2676.
  3. Gisondi P, Lora V, Bonauguri C, Russo A, Lippi G, Girolomoni G. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br J Dermatol. 2013;168(4):749-755.
  4. Gisondi P, Galvan A, Idolazzi L, Girolomoni G. Management of moderate to severe psoriasis in patients with metabolic comorbidities. Front Med (Lausanne). 2015;2:1.
  5. Prussick RB, Miele L. Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden? Br J Dermatol. 2018;179(1):16-29.
  6. Scher JU, Ogdie A, Merola JF, Ritchlin C. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-166.
  7. Gisondi P, Tinazzi I, El-Dalati G, et al. Lower limb enthesopathy in patients with psoriasis without clinical signs of arthropathy: a hospital-based case-control study. Ann Rheum Dis. 2008;67(1):26-30.
  8. Tinazzi I, McGonagle D, Biasi D, et al. Preliminary evidence that subclinical enthesopathy may predict psoriatic arthritis in patients with psoriasis. J Rheumatol. 2011;38(12):2691-2692.
  9. Gisondi P, Girolomoni G. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors. Semin Thromb Hemost. 2009;35(3):313-324.
  10. Mak RKH, Hundhausen C, Nestle FO. Progress in understanding the immunopathogenesis of psoriasis. Actas Dermosifiliogr. 2009;100 Suppl 2:2-13.
  11. World Health Organization. (‎2016)‎. Global report on psoriasis. World Health Organization. https://apps.who.int/iris/handle/10665/204417
  12.  Armstrong AW, Schupp C, Wu J, Bebo B. Quality of life and work productivity impairment among psoriasis patients: findings from the National Psoriasis Foundation survey data 2003-2011. PLoS One. 2012;7(12):e52935.
  13. Ljosaa TM, Stubhaug A, Mork C, Moum T, Wahl AK. Improvement in Psoriasis Area and Severity Index score predicts improvement in skin pain over time in patients with psoriasis. Acta Derm Venereol. 2013;93(3):330-334.
  14. Chen A, Beck KM, Tan E, Koo J. Stigmatization in Psoriasis. Journal of Psoriasis and Psoriatic Arthritis. 2018;3(3):100-106.
  15. Ferreira BR, Pio-Abreu JL, Reis JP, Figueiredo A. Analysis of the prevalence of mental disorders in psoriasis: the relevance of psychiatric assessment in dermatology. Psychiatr Danub. 2017;29(4):401-406.
  16. Shi Y, Song R, Wang L, et al. Identifying Plasma Biomarkers with high specificity for major depressive disorder: A multi-level proteomics study. J Affect Disord. 2020;277:620-630.
  17. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-895.
  18. Koo J, Marangell LB, Nakamura M, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. J Eur Acad Dermatol Venereol. 2017;31(12):1999-2009.
  19. Patel N, Nadkarni A, Cardwell LA, et al. Psoriasis, depression, and inflammatory overlap: a review. Am J Clin Dermatol. 2017;18(5):613-620.
  20. Maurer DM. Screening for depression. Am Fam Physician. 2012;85(2):139-144.
  21. Hoyl MT, Alessi CA, Harker JO, et al. Development and testing of a five-item version of the Geriatric Depression Scale. J Am Geriatr Soc. 1999;47(7):873-878.
  22. Strober B, Gooderham M, de Jong EMGJ, et al. Depressive symptoms, depression, and the effect of biologic therapy among patients in Psoriasis Longitudinal Assessment and Registry (Psolar). J Am Acad Dermatol. 2018;78(1):70-80.
  23. Conrad C, Di Domizio J, Mylonas A, et al. TNF blockade induces a dysregulated type I interferon response without autoimmunity in paradoxical psoriasis. Nat Commun. 2018;9(1):25.

Search:

Filter by Topic:


We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK